首页>投融资
Prometheus Biosciences
收并购
The company profile has not been updated since June 2023, when Prometheus Biosciences was acquired by Merck & Co.The company previously maintained a website at www.prometheusbiosciences.comPrometheus Biosciences was a biopharmaceutical company focused on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with significant unmet medical needs in inflammatory bowel disease.In April 2023, the company and Merck & Co entered into a definitive agreement, whereby Merck would acquire all of the outstanding shares of the company for USD 200.00 per share for a total equity value of approximately USD 10.8 billion. The acquisition was subjected to the company shareholder approval as well as other closing conditions, inclduing the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction was expected to close in the third quarter of 2023. In June
基本信息
-
公司全称Prometheus Biosciences Inc
-
类型生物制药商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数101~500人
-
地址3050 Science Park Road #342 SAN DIEGO CALIFORNIA 92121; US; Telephone: +18584224300;
-
联系电话32 1 039 43 00
-
邮箱contact@promethera.com
-
成立时间2009-01-01
投融资
-
2023-06-16收并购未透露Merck Group
-
2021-03-12上市1.9亿美元未透露
-
2020-11-09股权融资1.3亿美元Point 72鱼鹰资管Eventide Asset ManagementPerceptive AdvisorsRTW InvestmentsGIBLIBIrving InvestorsAscend Global InvestmentCowen Healthcare Investments
-
2019-12-16D轮750万欧元Innovation Grade VenturesPegasus Tech Ventures
-
2019-05-06D轮3970万欧元ITOCHU Corporation
-
2018-04-10未透露930万欧元Shinsei Corporate Investment Limited
-
2016-10-28C轮1000万欧元SRIW勃林格殷格翰风险基金SMS InvestmentsMercer Investment ManagementFund +Vesalius Biocapital
-
2012-03-28B轮2360万欧元ShireMitsui & Co. Global Investment勃林格殷格翰风险基金
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国)：Veradermics是一家位于美国的生物技术公司，专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台，开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息